Status:
RECRUITING
Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1
Lead Sponsor:
Augusta University
Conditions:
Type 1 Diabetes
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
The proposed study is designed to test the hypothesis that treatment of resveratrol for 12 weeks will improve both endothelin-B receptor (aim 1) and skeletal muscle mitochondrial function (aim 2) in p...
Detailed Description
Preliminary data from the investigators' laboratory demonstrate a negative relationship between hemoglobin A1c (HbA1c) and ETBR function, supporting ETBR may be dysfunctional in the presence of T1D. U...
Eligibility Criteria
Inclusion
- Men and premenopausal women
- All races
- Clinical diagnosis of insulin-dependent type 1 diabetes (patients only)
Exclusion
- Clinical diagnosis of hepatic, cardiovascular, or renal disease
- Uncontrolled diabetes (HbA1C \>12%)
- Diabetic complications (i.e. neuropathy)
- Uncontrolled hypertension (\>140/90 mm Hg on therapy)
- Pregnancy
- Use of vasoactive medications
Key Trial Info
Start Date :
October 14 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2027
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04449198
Start Date
October 14 2020
End Date
July 1 2027
Last Update
January 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Augusta University/Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology
Augusta, Georgia, United States, 30912